1025504-45-3

Basic information

• Product Name: Valbenazine
• Synonyms: Valbenazine
• CAS NO: 1025504-45-3
• Molecular Formula: C₂₄H₃₈N₂O₄
• Molecular Weight: 418.56952
• Mol File: 1025504-45-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 507.2±50.0 °C(Predicted)
• Appearance: /
• Density: 1.11±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 7.76±0.33(Predicted)
• CAS DataBase Reference: Valbenazine(CAS DataBase Reference)
• NIST Chemistry Reference: Valbenazine(1025504-45-3)
• EPA Substance Registry System: Valbenazine(1025504-45-3)

Safety Data

• Hazardous Substances Data: 1025504-45-3(Hazardous Substances Data)

Usage

Uses

Valbenzine is a highly selective vesicular monoamine transporter 2 inhibitor. It is used in the treatment of tardive dykinesia.

Upstream product

• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 1026016-83-0 ((3R,11bR)-3-isobutyl-9.10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one) 
• 58-46-8 (3R^*,11bR^*)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzoquinolizin-2-one 
• 1025504-76-0 (S)-2-benzyloxycarbonyl-amino-3-methylbutyric acid-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester 

Downstream Products

• 1639208-54-0 (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl (S)-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 

Relevant articles and documents

Crystalline forms of valbenazine ditosylate

Disclosed herein are new crystalline forms of valbenazine ditosylate designated Form D and Form E, which are characterized using one or more analytical methods, such as X-ray Powder Diffraction analysis. Further disclosed herein are crystalline Form D valbenazine ditosylate in the form of a dichloromethane solvate, and crystalline Form E valbenazine ditosylate in the form of a hydrate. Also disclosed are pharmaceutical compositions comprising these new crystalline forms, and methods of using those compositions for the treatment of various disease states and conditions, including hyperkinetic disorder, such as drug-induced tardive dyskinesia and Tourette's syndrome.

SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO

Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol compounds are disclosed that are inhibitors of the vesicular monoamine transporter 2 (VMAT2). The compounds of this invention have the structure (I): wherein R1 is as defined herein, including stereoisomers and pharmaceutically acceptable salts and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use in a subject in need thereof.